Toggle menu

NOVEL Study

Start date:
May/June 2018
Co-ordinated by:
LumiraDx
Main trial site:
Royal Infirmary Edinburgh

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Primary Objective: evaluation of diagnostic platform with biomarkers useful in emergency settings.

Sample: Patients over 18 years old presenting to the Emergency Department with mainly symptoms of cardiovascular conditions.

Trial Design: Prospective observational (cohort) feasibility study

Chief Investigator

Professor Alasdair Gray

Co-Director of EMERGE & Clinical Director of the Emergency Department

Research Team

Dr Adam Lloyd

Honorary Research Fellow & Lecturer

Alison Grant

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

Polly Black

Senior Research Nurse

Mia Paderanga

Senior Research Nurse

Rachel O'Brien

Lead Research Nurse

More EMERGE Trials

Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.

Read more

RAPID-CTCA

Evaluating the role of early CT Coronary Angiography

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Read more

PRECISE- CTCA

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)